The FDA has granted breakthrough therapy designation (BTD) to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the treatment of adult patients with HER2-positive early breast cancer who have ...
It's not too late to turn the page on old habits and start reading again in 2026. People often stop reading in adulthood because they're fatigued from school book assignments or just don't have the ...
Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants rega ...
Novel adjunct treatments for posttraumatic stress disorder: Neurofeedback and deep brain reorienting
Dr. Lanius discusses the need for novel adjunct treatments for posttraumatic stress disorder (PTSD), highlighting two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback